Skip to main content
Erschienen in: Supportive Care in Cancer 6/2009

01.06.2009 | Original Article

Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center

verfasst von: Amy P. Abernethy, Sally Y. Barbour, Hope Uronis, S. Yousuf Zafar, April Coan, Krista Rowe, Mary Ruth Pupa, Jane L. Wheeler, James E. Herndon II

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Goals

Management of the risk of potential chemotherapy-induced neutropenic complications such as febrile neutropenia (FN) and severe neutropenia (SN) is a quality of care priority. How frequently does care at our institution conform to established guidelines?

Materials and methods

This retrospective chart review study included a random sample of 305 cancer patients receiving care at a single US academic medical center. Abstracted data included demographics, risk factors, and outcome variables (e.g., development of FN/SN, administration of myeloid growth factors). To evaluate quality of care, we assessed conformance between actual practice and established clinical practice guidelines for the use of myeloid growth factors from the National Comprehensive Cancer Network (NCCN).

Main results

Of the 305 cases reviewed, 8% were classified as low risk (<10%), 48% as intermediate risk (10–20%), and 44% as high risk (>20%), using the risk classifications in the NCCN guidelines modified to accommodate illness and other risk factors. Thirty-four percent received prophylactic administration of myeloid growth factors. Half of the cases had adequate documentation of mid-cycle absolute neutrophil count to determine whether FN/SN developed. Among these cases with adequate documentation, 21% developed FN/SN. Use of growth factors did not conform to established quality guidelines. Overall, 77 of 133 (58%) high-risk cases received myeloid growth factors, whereas six of 25 (24%) low-risk cases received myeloid growth factors.

Conclusions

Routine clinical practice in this academic oncology setting was poorly aligned with established guidelines; there is substantial opportunity to standardize clinical strategies and increase conformance with evidence-based guidelines.
Literatur
1.
Zurück zum Zitat Fischer DS, Durivage HJ, Knobf MT et al (2003) The cancer chemotherapy handbook, 6th edn. Mosby, St. Louis, MO Fischer DS, Durivage HJ, Knobf MT et al (2003) The cancer chemotherapy handbook, 6th edn. Mosby, St. Louis, MO
3.
Zurück zum Zitat Bodey GP, Buckley M, Sathe YS et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340PubMed Bodey GP, Buckley M, Sathe YS et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340PubMed
7.
8.
Zurück zum Zitat Pinto L, Liu Z, Doan Q et al (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295. doi:10.1185/030079907X219599 PubMedCrossRef Pinto L, Liu Z, Doan Q et al (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295. doi:10.​1185/​030079907X219599​ PubMedCrossRef
10.
Zurück zum Zitat Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184. doi:10.1200/JCO.2005.09.102 PubMedCrossRef Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184. doi:10.​1200/​JCO.​2005.​09.​102 PubMedCrossRef
11.
Zurück zum Zitat Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984. doi:10.1200/JCO.2004.00.7955 PubMedCrossRef Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984. doi:10.​1200/​JCO.​2004.​00.​7955 PubMedCrossRef
12.
Zurück zum Zitat American Society of Clinical Oncology (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Accessed online May 27, 2008 American Society of Clinical Oncology (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Accessed online May 27, 2008
13.
Zurück zum Zitat Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453. doi:10.1016/j.ejca.2006.05.002 PubMedCrossRef Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453. doi:10.​1016/​j.​ejca.​2006.​05.​002 PubMedCrossRef
14.
Zurück zum Zitat NCCN (2008) Clinical Practice Guidelines in Oncology Myeloid Growth Factors. National Comprehensive Cancer Network V.1.2008 NCCN (2008) Clinical Practice Guidelines in Oncology Myeloid Growth Factors. National Comprehensive Cancer Network V.1.2008
15.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed
16.
Zurück zum Zitat Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560. doi:10.1007/s00520-004-0614-5 PubMedCrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560. doi:10.​1007/​s00520-004-0614-5 PubMedCrossRef
17.
Zurück zum Zitat Dale DC, Cosler LE, Wolf D et al Poster 6107: Economic analysis of prophylactic granulocyte colony-stimulating factor use based on a risk model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, 2006 Dale DC, Cosler LE, Wolf D et al Poster 6107: Economic analysis of prophylactic granulocyte colony-stimulating factor use based on a risk model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, 2006
18.
Zurück zum Zitat Cosler LE, Calhoun EA, Agboola O et al (2004) Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24:488–494. doi:10.1592/phco.24.5.488.33360 PubMedCrossRef Cosler LE, Calhoun EA, Agboola O et al (2004) Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24:488–494. doi:10.​1592/​phco.​24.​5.​488.​33360 PubMedCrossRef
20.
Zurück zum Zitat Lyman GH, Kuderer NM, Crawford J et al (2008) Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), pp 8561 Lyman GH, Kuderer NM, Crawford J et al (2008) Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), pp 8561
Metadaten
Titel
Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center
verfasst von
Amy P. Abernethy
Sally Y. Barbour
Hope Uronis
S. Yousuf Zafar
April Coan
Krista Rowe
Mary Ruth Pupa
Jane L. Wheeler
James E. Herndon II
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0562-6

Weitere Artikel der Ausgabe 6/2009

Supportive Care in Cancer 6/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.